Recent data details the results of treatment with botulinum toxin versus strabismus surgery for acute acquired concomitant esotropia (AACE).
AACE is a rare, distinct subtype of esotropia. It is characterized by sudden onset of simultaneous esotropia, where the eyes turn inward, and cause double vision.
Botulinum toxin is an alternative therapy to strabismus surgery, the conventional treatment of AACE.
Recently, Nguyen and colleagues published their results testing botulinum toxin to treat AACE. This clinical trial was a multicenter, retrospective, nonrandomized, comparative, noninferiority study. In total, 76 children with AACE were followed for at least 36 months after treatment with either botulinum toxin or strabismus surgery. The main outcome measure was success rate at 36 months.
At 36 months, the success rate for the botulinum toxin group was 72% and 56% for the surgery group. Both groups had similar median deviation and median stereoacuity. Based on these results, botulinum toxin was observed to be noninferior to surgery at 36 months. At 36 months, the median time from esotropia onset to any intervention was 6.5 months without treatment success and 4 months in those with treatment success.
For more information, click here.
To learn more about rare eye conditions, visit https://checkrare.com/diseases/ophthalmology-eye-diseases/
References:
Nguyen MTB, et al. Three-year Outcomes of Botulinum Toxin Versus Strabismus Surgery for the Treatment of Acute Acquired Comitant Esotropia in Children. Amer JOphthal. 2025 [in press]. https://www.ajo.com/article/S0002-9394(25)00001-7/abstract